drugset / Trial / NCT07683806
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
Phase 3
Not yet recruiting
309 enrolled
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Arcutis Biotherapeutics, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
Timeline
- Start
- 2026-08-24
- Primary completion
- 2027-06-30
- Completion
- 2027-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Roflumilast | Small molecule | 0.3 % | Topical |